A new treatment for type 1 diabetes using a small molecule
A dual-acting small molecule for the treatment of type 1 diabetes
This study is testing a new treatment that could help people with type 1 diabetes by protecting their insulin-producing cells and helping them make more insulin, which might lead to better blood sugar control.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Asake Biotechnology, LLC NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10880698 on NIH RePORTER |
What this research studies
This research investigates a novel small-molecule therapy aimed at treating type 1 diabetes (T1D), an autoimmune condition that severely affects insulin production. The approach focuses on protecting insulin-producing beta cells from damage caused by inflammatory signals while also enhancing their ability to produce insulin. By conducting experiments on both rodent models and human pancreatic cells, the researchers aim to demonstrate the effectiveness of this treatment in preventing blood glucose spikes and reducing autoimmune activity. If successful, this therapy could provide a new avenue for managing T1D beyond traditional insulin therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes, particularly those experiencing significant challenges in managing their blood glucose levels.
Not a fit: Patients with type 2 diabetes or those whose diabetes is not autoimmune in nature may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that improves insulin production and protects pancreatic cells in patients with type 1 diabetes.
How similar studies have performed: While there have been advancements in beta-cell health research, this specific approach using a dual-acting small molecule is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Athens, United States
- Asake Biotechnology, LLC — Athens, United States (Active)
Researchers
- Principal investigator: Wu, Shiyong — Asake Biotechnology, LLC
- Study coordinator: Wu, Shiyong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.